Sativex-induced neurobehavioral effects: Causal or concausal? A practical advice!

Research output: Contribution to journalArticlepeer-review

Abstract

Nabiximols (Sativex) is an oromucosal spray, containing delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), used as treatment for unresponsive spasticity in multiple sclerosis (MS) patients. Sativex is thought to not affect cognition or induce any psychiatric problem at the doses generally used. Nonetheless, it is known that the concomitant use of more than one muscle-relaxant drugs can result in additive neuropsychiatric effects. Herein we describe a case of a woman affected by MS and treated with baclofen and methylprednisolone, who developed important behavioral changes, including suicidal ideation, after 4 weeks of Sativex administration. We are not completely able to state if Sativex alone was responsible for our patient's psychiatric symptoms, in reason of the concomitant use of the other drugs. In conclusion, physicians should pay more attention when prescribing drugs to MS patients affected by spasticity, including Sativex, since neurobehavioral side effects may emerge especially in predisposed individuals.

Original languageEnglish
Article number25
JournalDARU, Journal of Pharmaceutical Sciences
Volume23
Issue number1
DOIs
Publication statusPublished - Apr 17 2015

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Sativex-induced neurobehavioral effects: Causal or concausal? A practical advice!'. Together they form a unique fingerprint.

Cite this